EI
VRCA icon

EAM Investors’s Verrica Pharmaceuticals VRCA Stock Holding History

EAM Investors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,059
Closed -$515K – 341
2024
Q2 		$515K Buy
+7,059
New +$542K 0.08% 228
2023
Q2 		– Sell
-20,907
Closed -$1.36M – 378
2023
Q1 		$1.36M Buy
+20,907
New +$1.26M 0.27% 187

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EAM Investors's VRCA Position: Q3 2024 in Review

EAM Investors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2024, closing a stake of 7,059 shares — an estimated $515K sold.

EAM Investors first reported a position in VRCA in Q1 2023 and held it in 2 quarters. The position peaked at $1.36M in Q1 2023. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

  • EAM Investors reported no remaining Verrica Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • EAM Investors sold 7,059 Verrica Pharmaceuticals shares in Q3 2024, an estimated $515K.
  • EAM Investors first reported a position in Verrica Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • EAM Investors's Verrica Pharmaceuticals position peaked at $1.36M in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on EAM Investors's 13F filing for Q3 2024, filed 13 Nov 2024.